MiNK Therapeutics opened lower at $10.20, compared with its previous close of $10.22. In the last trading session, the stock traded between $10.02 and $10.38. It showed a downward intraday trend.
An investment of $100 made 5 years ago in MiNK Therapeutics is now worth
$ 4.78
Resulting in a loss of
$ 95.22 (95.22%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.65 (-6.40%)
Day High
$10.38
Day Low
$10.02
Day Open
$10.20
Prev Close
$10.22
Volume
14,396
1W Return
-11.06%
1M Return
-8.73%
3M Return
-14.74%
6M Return
-12.60%
1Y Return
-29.94%
Market Cap ($ Mn)
49
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
372.05%
EPS (TTM)
$-0.61
1 Week
-11.06%
1 Month
-8.73%
3 Months
-14.74%
6 Months
-12.60%
9 Months
-13.39%
MiNK Therapeutics Q1FY26 Results: Loss narrows to $0.57 per share
Q1FY26 loss per share narrowed to $0.57 from $0.70 in Q1FY25. Net loss decreased to $2.7 million from $2.8 million year-over-year. Cash position stands at $9.5 million with a 12-month operational runway. Initiated randomized phase 2 trial for Agent 797 in ARDS with 90 patients. Secured non-dilutive support via See Further collaboration for pediatric cancers.
YesterdayMiNK Therapeutics presents preclinical cancer data for iNKT platform at SITC 2026
MiNK Therapeutics presented preclinical data at SITC 2026 addressing tumor resistance mechanisms. AgenT-797 combined with checkpoint inhibitors increased tumor-cell killing in colorectal cancer models. MiNK-215 demonstrated senolytic activity and stromal targeting in collaboration with Imperial College London. Q3FY26 results scheduled for release on November 11, 2026, with conference call at 8:30 am ET.
6 days agoHC Wainwright initiates MiNK Therapeutics at buy with $38 price target
HC Wainwright & Co. initiated coverage on MiNK Therapeutics. Analyst Matthew Keller assigned a Buy rating. Price target set at $38 per share.
8 days agoB. Riley raises MiNK Therapeutics price target to $50
B. Riley Securities reiterated a Buy rating on MiNK Therapeutics. Price target increased from $43 to $50 per share. Analyst Mayank Mamtani issued the revised valuation.
22 days agoMiNK Therapeutics to present colorectal cancer data at SITC 2026
MiNK Therapeutics to present two posters at SITC 41st Annual Meeting. AgenT-797 data shown for checkpoint inhibitor-resistant colorectal cancer. MiNK-215 presented for eliminating senescent tumor cells and fibroblasts. Presentations scheduled for November 6 and 7, 2026, in Phoenix.
1mo agoMiNK Therapeutics selected for $87M ARPA-H cell therapy initiative
MiNK Therapeutics' agenT-797 platform selected for ARPA-H BioStabilization Systems (BoSS) program. ARPA-H commits up to $87 million to enable room-temperature storage for cell therapies. Goal is a 200-degree leap from -196°C cryogenic storage to 21°C ambient conditions. MiNK joins RAB team led by Draper Laboratory to develop AI-assisted stabilization techniques.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in MiNK Therapeutics is now worth
$ 4.78
Resulting in a loss of
$ 95.22 (95.22%)
Note: Past profits do not guarantee future returns.
